These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23407563)

  • 1. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.
    Srivastava N; VanderLaan PA; Kelly CP; Costa DB
    J Thorac Oncol; 2013 Mar; 8(3):e23-4. PubMed ID: 23407563
    [No Abstract]   [Full Text] [Related]  

  • 2. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib-induced pancreatic pseudocyst: a novel adverse event.
    Ishida H; Ichikawa W; Sasaki Y
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26351314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.
    Watanabe N; Nakahara Y; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Sakamoto K
    Acta Oncol; 2014 Jan; 53(1):158-60. PubMed ID: 23750540
    [No Abstract]   [Full Text] [Related]  

  • 5. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
    Tartarone A; Gallucci G; Lazzari C; Lerose R; Lombardi L; Aieta M
    Future Oncol; 2015; 11(14):2043-8. PubMed ID: 26198834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A; Wood K; Salgia R
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.
    Brosseau S; Gounant V; Choudat L; Pluvy J; Zalcman G; Khalil A
    Diagn Interv Imaging; 2018 Apr; 99(4):267-268. PubMed ID: 29472032
    [No Abstract]   [Full Text] [Related]  

  • 8. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Crystal AS; Shaw AT
    Clin Cancer Res; 2012 Sep; 18(17):4479-81. PubMed ID: 22912388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
    Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
    Koizumi T; Fukushima T; Tatai T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S
    Lung Cancer; 2015 Apr; 88(1):112-3. PubMed ID: 25678258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
    Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
    Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
    Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
    Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
    Gautschi O; Schefer H; Riklin C; Strobel K; Diebold J
    Onkologie; 2013; 36(6):342-7. PubMed ID: 23774148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
    Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
    J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
    [No Abstract]   [Full Text] [Related]  

  • 17. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
    Girard N; Audigier-Valette C; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlési F
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):225-33. PubMed ID: 25413260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
    Browning ET; Weickhardt AJ; Camidge DR
    J Thorac Oncol; 2013 Mar; 8(3):e21. PubMed ID: 23407562
    [No Abstract]   [Full Text] [Related]  

  • 19. Crizotinib-associated erythema multiforme in a lung cancer patient.
    Sawamura S; Kajihara I; Ichihara A; Fukushima S; Jinnin M; Yamaguchi E; Kohrogi H; Ihn H
    Drug Discov Ther; 2015 Apr; 9(2):142-3. PubMed ID: 25994067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
    J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.